-
公开(公告)号:US20160237148A1
公开(公告)日:2016-08-18
申请号:US15144574
申请日:2016-05-02
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor: Lynn MACDONALD , Richard TORRES , Marc R. MORRA , Joel H. MARTIN , Joel C. REINHARDT , Paul TISEO
IPC: C07K16/22 , A61K39/395 , A61K45/06 , A61K9/00
CPC classification number: C07K16/22 , A61K9/0019 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/76
Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.
-
公开(公告)号:US20190211090A1
公开(公告)日:2019-07-11
申请号:US16282120
申请日:2019-02-21
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor: Lynn MACDONALD , Richard TORRES , Marc R. MORRA , Joel H. MARTIN , Joel C. REINHARDT , Paul TISEO
IPC: C07K16/22 , A61K45/06 , A61K9/00 , A61K39/395
Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.
-
公开(公告)号:US20200339672A1
公开(公告)日:2020-10-29
申请号:US16926232
申请日:2020-07-10
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor: Lynn MACDONALD , Richard TORRES , Marc R. MORRA , Joel H. MARTIN , Joel C. REINHARDT , Paul TISEO
IPC: C07K16/22 , A61K39/395 , A61K45/06 , A61K9/00
Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.
-
-